Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

被引:32
作者
Kim, Jung Eun [1 ]
Choi, Hyoung Chul [1 ]
机构
[1] Yeungnam Univ, Coll Med, Dept Pharmacol, Aging Associated Vasc Dis Res Ctr, Taegu 705717, South Korea
关键词
AMP-activated protein kinase (AMPK); Angiotensin II type 1 (AT(1)) receptor antagonist; Losartan; Vascular smooth muscle cells (VSMCs); Proliferation; SPONTANEOUSLY HYPERTENSIVE-RATS; AT(1) RECEPTOR ANTAGONIST; FATTY-ACID OXIDATION; ANGIOTENSIN-II; INSULIN-RESISTANCE; GLUCOSE-UPTAKE; IN-VIVO; ATHEROSCLEROSIS; IDENTIFICATION; TELMISARTAN;
D O I
10.4196/kjpp.2010.14.5.299
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Losartan is a selective angiotensin II (Ang II) type 1 (AT(1)) receptor antagonist which inhibits vascular smooth muscle cells (VSMCs) contraction and proliferation We hypothesized that losartan may prevent cell proliferation by activating AMP-activated protein kinase (AMPK) in VSMCs VSMCs were treated with various concentrations of losartan AMPK activation was measured by Western blot analysis and cell proliferation was measured by MTT assay and flowcytometry Losartan dose- and time-dependently increased the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase (ACC) in VSMCs Losartan also significantly decreased the Ang II- or 15% FBS-induced VSMC proliferation by inhibiting the expression of cell cycle associated proteins, such as p-Rb, cyclin D, and cyclin E Compound C, a specific inhibitor of AMPK, or AMPK siRNA blocked the losartan-induced inhibition of cell proliferation and the G(0)/G(1) cell cycle arrest These data suggest that losartan-induced AMPK activation might attenuate Ang II-induced VSMC proliferation through the inhibition of cell cycle progression
引用
收藏
页码:299 / 304
页数:6
相关论文
共 32 条
[1]
Targeting effective blood pressure control with angiotensin receptor blockers [J].
Asmar, R .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (03) :315-320
[2]
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[3]
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. [J].
Bolster, DR ;
Crozier, SJ ;
Kimball, SR ;
Jefferson, LS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :23977-23980
[4]
RECEPTOR-MEDIATED EFFECTS OF ANGIOTENSIN-II ON GROWTH OF VASCULAR SMOOTH-MUSCLE CELLS FROM SPONTANEOUSLY HYPERTENSIVE RATS [J].
BUNKENBURG, B ;
VANAMELSVOORT, T ;
ROGG, H ;
WOOD, JM .
HYPERTENSION, 1992, 20 (06) :746-754
[5]
RETRACTED: Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo (Retracted article. See vol. 294, pg. 10742, 2019) [J].
Choi, Hyoung Chul ;
Song, Ping ;
Xie, Zhonglin ;
Wu, Yong ;
Xu, Jian ;
Zhang, Miao ;
Dong, Yunzhou ;
Wang, Shuangxi ;
Lau, Kai ;
Zou, Ming-Hui .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (29) :20186-20197
[6]
An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes [J].
Fujimoto, M ;
Masuzaki, H ;
Tanaka, T ;
Yasue, S ;
Tomita, T ;
Okazawa, K ;
Fujikura, J ;
Chusho, H ;
Ebihara, K ;
Hayashi, T ;
Hosoda, K ;
Nakao, K .
FEBS LETTERS, 2004, 576 (03) :492-497
[7]
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension [J].
Furuhashi, M ;
Ura, N ;
Higashiura, K ;
Murakami, H ;
Tanaka, M ;
Moniwa, N ;
Yoshida, D ;
Shimamoto, K .
HYPERTENSION, 2003, 42 (01) :76-81
[8]
Management of cellular energy by the AMP-activated protein kinase system [J].
Hardie, DG ;
Scott, JW ;
Pan, DA ;
Hudson, ER .
FEBS LETTERS, 2003, 546 (01) :113-120
[9]
New roles for the LKB1→AMPK pathway [J].
Hardie, DG .
CURRENT OPINION IN CELL BIOLOGY, 2005, 17 (02) :167-173